These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
167 related items for PubMed ID: 23428906
1. Current biodefense vaccine programs and challenges. Wolfe DN, Florence W, Bryant P. Hum Vaccin Immunother; 2013 Jul; 9(7):1591-7. PubMed ID: 23428906 [Abstract] [Full Text] [Related]
3. Drugs and vaccines for biological weapons. Med Lett Drugs Ther; 2001 Oct 15; 43(1115):87-9. PubMed ID: 11606896 [No Abstract] [Full Text] [Related]
4. Biological threat characterization research: a critical component of national biodefense. Petro JB, Carus WS. Biosecur Bioterror; 2005 Oct 15; 3(4):295-308. PubMed ID: 16366839 [Abstract] [Full Text] [Related]
5. Advances in the development of next-generation anthrax vaccines. Friedlander AM, Little SF. Vaccine; 2009 Nov 05; 27 Suppl 4():D28-32. PubMed ID: 19837282 [Abstract] [Full Text] [Related]
6. Surveillance for adverse events associated with anthrax vaccination--U.S. Department of Defense, 1998-2000. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 2000 Apr 28; 49(16):341-5. PubMed ID: 10817479 [Abstract] [Full Text] [Related]
8. Drugs and vaccines against biological weapons. Conn Med; 2001 Dec 28; 65(12):719-20. PubMed ID: 11797482 [No Abstract] [Full Text] [Related]
9. Medical aspects of bio-terrorism. Balali-Mood M, Moshiri M, Etemad L. Toxicon; 2013 Jul 28; 69():131-42. PubMed ID: 23339855 [Abstract] [Full Text] [Related]
13. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Middlebrook JL. Adv Drug Deliv Rev; 2005 Jun 17; 57(9):1415-23. PubMed ID: 15896873 [Abstract] [Full Text] [Related]
14. The Defense Threat Reduction Agency: a note on the United States' approach to the threat of chemical and biological warfare. Linkie M. J Contemp Health Law Policy; 2000 Jun 17; 16(2):531-63. PubMed ID: 10970184 [No Abstract] [Full Text] [Related]
15. [New challenges in the biological weapons convention]. Sissonen S, Raijas T, Haikala O, Hietala H, Virri M, Nikkari S. Duodecim; 2012 Jun 17; 128(3):283-9. PubMed ID: 22428382 [Abstract] [Full Text] [Related]
16. Development pathway for biodefense vaccines. Barrett AD, Beasley DW. Vaccine; 2009 Nov 05; 27 Suppl 4():D2-7. PubMed ID: 19837280 [Abstract] [Full Text] [Related]
17. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Rusnak JM, Kortepeter MG, Hawley RJ, Anderson AO, Boudreau E, Eitzen E. Biosecur Bioterror; 2004 Nov 05; 2(4):281-93. PubMed ID: 15650438 [Abstract] [Full Text] [Related]
18. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Reichert E, Clase A, Bacetty A, Larsen J. Biosecur Bioterror; 2009 Dec 05; 7(4):413-27. PubMed ID: 20028250 [Abstract] [Full Text] [Related]
19. Bioterrorism: pathogens as weapons. Anderson PD, Bokor G. J Pharm Pract; 2012 Oct 05; 25(5):521-9. PubMed ID: 23011963 [Abstract] [Full Text] [Related]
20. Technical transformation of biodefense vaccines. Lu S, Wang S. Vaccine; 2009 Nov 05; 27 Suppl 4(0 4):D8-D15. PubMed ID: 19837293 [Abstract] [Full Text] [Related] Page: [Next] [New Search]